Takao Saito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3007862/publications.pdf

Version: 2024-02-01

172457 155660 3,134 73 29 55 h-index citations g-index papers 79 79 79 2248 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Proposal for diagnostic criteria for IgG4-related kidney disease. Clinical and Experimental Nephrology, 2011, 15, 615-626.	1.6	377
2	The Role of Macrophages in Diabetic Glomerulosclerosis. American Journal of Kidney Diseases, 1993, 21, 480-485.	1.9	278
3	Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney International, 2004, 65, 1400-1407.	5.2	147
4	Lipoprotein Glomerulopathy: Glomerular Lipoprotein Thrombi in a Patient With Hyperlipoproteinemia. American Journal of Kidney Diseases, 1989, 13, 148-153.	1.9	144
5	The clinical course of patients with IgG4-related kidney disease. Kidney International, 2013, 84, 826-833.	5.2	144
6	Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clinical and Experimental Nephrology, 2011, 15, 493-503.	1.6	127
7	Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clinical and Experimental Nephrology, 2013, 17, 155-173.	1.6	111
8	The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney International, 1987, 32, 691-699.	5.2	103
9	Contribution of mononuclear leucocytes to the progression of experimental focal glomerular sclerosis. Kidney International, 1990, 37, 1076-1083.	5.2	94
10	Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clinical and Experimental Nephrology, 2012, 16, 903-920.	1.6	91
11	Impact of Lipoprotein Glomerulopathy on the Relationship Between Lipids and Renal Diseases. American Journal of Kidney Diseases, 2006, 47, 199-211.	1.9	79
12	A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney International, 1999, 56, 421-427.	5.2	74
13	Membranoproliferative Glomerulonephritis-Like Glomerular Disease and Concurrent Tubulointerstitial Nephritis Complicating IgG4-Related Autoimmune Pancreatitis. Internal Medicine, 2009, 48, 157-162.	0.7	68
14	Immunohistochemical Characteristics of IgG4-Related Tubulointerstitial Nephritis: Detailed Analysis of 20 Japanese Cases. International Journal of Rheumatology, 2012, 2012, 1-9.	1.6	62
15	Abnormal Lipoprotein and Apolipoprotein Pattern in Lipoprotein Glomerulopathy. American Journal of Kidney Diseases, 1991, 18, 553-558.	1.9	61
16	Lipoprotein Glomerulopathy. American Journal of Nephrology, 1993, 13, 64-68.	3.1	58
17	Virus-mediated Transduction of Apolipoprotein E (ApoE)-Sendai Develops Lipoprotein Glomerulopathy in ApoE-deficient Mice. Journal of Biological Chemistry, 2000, 275, 31269-31273.	3.4	52
18	Association of a Novel 3-Amino Acid Deletion Mutation of Apolipoprotein E (Apo E Tokyo) with Lipoprotein Glomerulopathy. Nephron, 1999, 83, 214-218.	1.8	49

#	Article	IF	Citations
19	Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clinical and Experimental Nephrology, 2015, 19, 379-386.	1.6	49
20	A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney International, 1999, 56, 1317-1323.	5.2	46
21	Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. Biochemical and Biophysical Research Communications, 2014, 448, 175-181.	2.1	44
22	A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clinical and Experimental Nephrology, 2004, 8, 117-26.	1.6	42
23	A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. Nephron Extra, 2015, 5, 58-66.	1.1	41
24	Lipoprotein Glomerulopathy: Renal Lipidosis Induced by Novel Apolipoprotein E Variants. Nephron, 1999, 83, 193-201.	1.8	40
25	Apolipoprotein E–related glomerular disorders. Kidney International, 2020, 97, 279-288.	5.2	38
26	Participation of macrophages in segmental endocapillary proliferation preceding focal glomerular sclerosis. Journal of Pathology, 1993, 170, 179-185.	4.5	33
27	Abnormal Lipid Metabolism and Renal Disorders Tohoku Journal of Experimental Medicine, 1997, 181, 321-337.	1.2	32
28	Lipoprotein glomerulopathy: Significance of lipoprotein and ultrastructural features. Kidney International, 1999, 56, S37-S41.	5. 2	32
29	Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clinical and Experimental Nephrology, 2016, 20, 87-93.	1.6	32
30	A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrology Dialysis Transplantation, 2007, 23, 751-756.	0.7	31
31	Immunohistological analysis for immunological response and mechanism of interstitial fibrosis in IgG4-related kidney disease. Modern Rheumatology, 2015, 25, 571-578.	1.8	29
32	Lipoprotein glomerulopathy: A new aspect of lipid induced glomerular injury. Nephrology, 1995, 1, 17-24.	1.6	25
33	Etiological Significance of Apolipoprotein E Mutations in Lipoprotein Glomerulopathy. Trends in Cardiovascular Medicine, 2002, 12, 67-70.	4.9	25
34	Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Research and Therapy, 2016, 18, 273.	3 . 5	25
35	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. EBioMedicine, 2015, 2, 456-466.	6.1	24
36	A Novel Mutation ApoE2 Kurashiki (R158P) in a Patient with Lipoprotein Glomerulopathy. Journal of Atherosclerosis and Thrombosis, 2011, 18, 536-541.	2.0	23

#	Article	IF	CITATIONS
37	Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR). Clinical and Experimental Nephrology, 2015, 19, 496-505.	1.6	23
38	A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrology Dialysis Transplantation, 2007, 23, 381-384.	0.7	22
39	Topics in lipoprotein glomerulopathy: an overview. Clinical and Experimental Nephrology, 2014, 18, 214-217.	1.6	22
40	Carnitine palmitoyltransferase II deficiency due to a novel gene variant in a patient with rhabdomyolysis and ARF. American Journal of Kidney Diseases, 2005, 45, 596-602.	1.9	21
41	Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. Clinical and Experimental Nephrology, 2014, 18, 220-224.	1.6	21
42	Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clinical and Experimental Nephrology, 2021, 25, 99-109.	1.6	20
43	Sequential studies of development of gastric carcinoma in dogs induced by N-methyl-N′-nitro-N-nitrosoguanidine. Cancer, 1978, 42, 1246-1254.	4.1	19
44	Significance of combined cyclosporinean prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clinical and Experimental Nephrology, 2014, 18, 784-794.	1.6	19
45	Histologic studies on the nephrotic syndrome in the elderly Tohoku Journal of Experimental Medicine, 1987, 153, 259-264.	1.2	16
46	Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses. Clinical and Experimental Nephrology, 2001, 5, 201-208.	1.6	16
47	Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrology Dialysis Transplantation, 2012, 27, 3899-3907.	0.7	16
48	Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clinical and Experimental Nephrology, 2009, 13, 430-437.	1.6	15
49	A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. Journal of Human Genetics, 2013, 58, 254-258.	2.3	15
50	Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. Kidney International, 2014, 85, 243-245.	5 . 2	15
51	Estimation of the number of histological diagnosis for IgG4-related kidney disease referred to the data obtained from the Japan Renal Biopsy Registry (J-RBR) questionnaire and cases reported in the Japanese Society of Nephrology Meetings. Clinical and Experimental Nephrology, 2017, 21, 97-103.	1.6	15
52	A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate. Case Reports in Nephrology and Dialysis, 2017, 7, 112-120.	0.6	14
53	Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. Clinical and Experimental Nephrology, 2017, 21, 961-970.	1.6	13
54	A Rare Cause of Posttransplantation Nephrotic Syndrome. American Journal of Kidney Diseases, 2005, 45, 1132-1138.	1.9	12

#	Article	IF	CITATIONS
55	Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. Clinical and Experimental Nephrology, 2012, 16, 115-121.	1.6	11
56	Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2. Case Reports in Nephrology and Dialysis, 2018, 8, 45-55.	0.6	11
57	Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease. Modern Pathology, 2018, 31, 890-899.	5.5	8
58	A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I. CEN Case Reports, 2018, 7, 127-131.	0.9	7
59	Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys). CEN Case Reports, 2018, 7, 225-228.	0.9	7
60	A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes. CEN Case Reports, 2019, 8, 106-111.	0.9	7
61	Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity. Clinical and Experimental Nephrology, 2007, 11, 174-179.	1.6	6
62	Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy. Case Reports in Nephrology and Dialysis, 2015, 5, 204-212.	0.6	6
63	A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka. Clinical Nephrology Case Studies, 2018, 6, 45-51.	0.7	6
64	Validation of the 2019 ACR/EULAR criteria for IgG4-related disease in a Japanese kidney disease cohort: a multicentre retrospective study by the IgG4-related kidney disease working group of the Japanese Society of Nephrology. Annals of the Rheumatic Diseases, 2021, 80, 956-957.	0.9	6
65	DNA cytophotometry on atypical glands in stomach carcinogenesis of dogs induced by N-methyl-N?-nitro-N-nitrosoguanidine. Journal of Cancer Research and Clinical Oncology, 1985, 109, 93-102.	2.5	5
66	Significance of a Novel Apolipoprotein E Variant, ApoE Osaka/Kurashiki, in Lipoprotein Glomerulopathy. Journal of Atherosclerosis and Thrombosis, 2011, 18, 542-543.	2.0	5
67	Differential Diagnosis (3): Sjögren Syndrome. , 2016, , 271-277.		1
68	Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka and Homozygous Apolipoprotein E2/2 without Dyslipidemia, with Characteristic Electron-Dense Deposits. Case Reports in Nephrology and Dialysis, 2022, 12, 96-104.	0.6	1
69	Association between HLA class II genotypes and IgA nephropathy in Japanese patients. Major Histocompatibility Complex, 2002, 8, 187-198.	0.1	O
70	Various Aspects of IgG4-related Disease. Internal Medicine, 2012, 51, 1157-1158.	0.7	0
71	The kidney and lipids: preface. Clinical and Experimental Nephrology, 2014, 18, 180-184.	1.6	0
72	Overview of IgG4-Related Kidney Disease. , 2016, , 75-83.		0

#	Article	IF	CITATIONS
73	Present status of ethics committees of the medical schools in Japan. The Tokushima Journal of Experimental Medicine, 1991, 38, 103-11.	0.1	O